The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (…
We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s…
The asthma therapy market consists of many well-established treatments, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s…
The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL…
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. However,…
Acute and chronic heart failure (HF) have distinct treatment pathways, and both are covered in this report. Although much progress has been made in the pharmacological management of HF, this…
Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. 2023 saw the…
The gastroesophageal cancer therapy market (including gastric, gastroesophageal junction, and esophageal cancer) is rapidly evolving and experiencing substantial growth, largely driven by the…
Migraine is a major public health concern in China, where it affects approximately 65 million people, making it the world’s largest migraine population. The disease is a heterogeneous condition…
The hemophilia A treatment landscape has evolved with the acceptance of Roche / Chugai’s nonfactor bispecific antibody Hemlibra as a key treatment. Offering improved treatment outcomes, Hemlibra…
The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6…
The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as…
Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in noninhibitor patients) and bypass agents (in…
Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets, according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…
Ten new brands entered the Parkinson’s disease (PD) market over the last decade (e.g., Acorda’s Inbrija, Sunovion’s Kynmobi, Neurocrine’s Ongentys), and additional new options are advancing…